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Effect of Prophylactic Fluconazole on the Frequency of Fungal Infections,
Amphotericin B Use, and Health Care Costs in Patients Undergoing Intensive
Chemotherapy for Hematologic Neoplasias
Andreas Schaffner and Maya Schaffner Laboratory of Clinical Mycology, Division ofInfectious Diseases,
Department ofMedicine, University Hospital, Zurich, Switzerland
Fungal infections are a major problem in patients with hematologic malignancy. Attempts to
reduce their frequency with antifungal agents have not been successful. A double-blind, controlled,
single-center trial was conducted with 96 consecutive patients undergoing 154episodes of chemother-
apy. Patients received 400 mg of fluconazole or placebo until bone marrow recovery or initiation of
intravenous amphotericin B infusions. End points were amphotericin B use, fungal infection, stable
neutrophil count >0.5 X 109/L, toxicity precluding further fluconazole use, and death. By Kaplan-
Meier estimation, the time to initiation of amphotericin B therapy was shorter in 76 patients treated
with placebo than in 75 treated with fluconazole (P = .003). Also, fluconazole reduced the number
of febrile days by 20% (P = .002) and prevented oropharyngeal candidiasis (1/75 vs. 9/76, P = .018).
The frequency of deep mycoses (8/76 vs. 8/75) and outcome were unaffected. Fluconazole did not
have a favorable effect on infection-related health care costs and was associated with prolonged
severe neutropenia (P = .01).
Systemic fungal infections are a major problem in patients
with hematologic neoplasias undergoing active chemotherapy
for remission induction. About 5%-20% of intensive chemo-
therapy episodes are complicated by invasive mycoses [1-4],
and deep fungal infection is found in 10%-40% of leukemia
patients at autopsy [5- 7]. In allogeneic bone marrow transplant
recipients, an even higher frequency of mycoses has been re-
ported from some centers [8]. Therefore, in most institutions,
amphotericin B is used empirically in all high-risk patients
with suspected fungal infection or unexplained fever refractory
to antibacterial therapy [9-13]. Filtration of environmental air
probably reduces the number of aerogenous infections with
molds, such as Aspergillus species; however, this approach is
expensive and not universally practicable, and it does not affect
the frequency of endogenous infections with yeasts colonizing
mucocutaneous surfaces [13]. Therefore, it would be desirable
to use prophylactic regimens with antifungal agents that affect
fungal colonization with yeasts and prevent candidiasis and
aspergillosis, the most common invasive mycoses.
To our knowledge, no controlled study has clearly shown
that antifungal prophylaxis affects outcome of intensive chemo-
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therapy for hematologic neoplasias, reduces the frequency of
invasive fungal infections in patients undergoing remission in-
duction of hematologic neoplasias, diminishes the empiric use
of amphotericin B, or reduces health care costs [2, 4, 14-
18]. However, prophylaxis favorably affects mycosis-related
morbidity and mortality in allogeneic bone marrow transplant
patients who have a high frequency (16%) of systemic candidi-
asis [8].
The present study was designed to investigate the effects of
fluconazole on the need for intravenous (iv) amphotericin B
and on the frequency of fungal infections in a center in which
aspergillosis is the predominant invasive mycosis [19]. In addi-
tion, the effect of prophylaxis on selected infection-related
health care costs was studied. Secondary analysis end points
included the duration of neutropenia and frequency of bacter-
emia in the study groups.
Patients and Methods
Patients. From 1 March 1990to 30 August 1993,we screened
all patients with acute myelogenous leukemia, lymphoblastic leu-
kemia, or recurrent high-grade malignant lymphoma who were
referred to our center for intensive chemotherapy that resulted in
an expected granulocytopenia of <0.5 X 109/L for ;;?;5 days. All
patients were enrolled and randomized during the study period,
and patients were randomized again for each subsequent hospital-
ization for chemotherapythat resulted in a new episode of neutro-
penia. Patients were excluded if they had been treated with sys-
temic antifungals within the preceding 7 days, had moderate or
severe liver dysfunction, as shown by an elevation of aspartate
amino transferase (AST) or alanine amino transferase (ALT) 3
times the normal value or a serum bilirubin level > 3 mg/dL, or
would not give informed consent. No patients were excluded due
to other exclusioncriteria (pregnancy,lactation,or age < 17years).
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Study protocol. Block randomization guaranteed that the pla-
cebo and study drug were evenly distributed over the study period.
Eligible patients were randomly assigned in blocks of 10 to receive
400 mg of fluconazole daily in capsules or as an infusion in 200
mL of saline or to receive an identically looking placebo, which
was prepared by Pfizer (Orsay, France) and distributed by the
hospital pharmacy. Stratified randomization guaranteed an equal
distribution of underlying diseases and chemotherapy: Patients re-
ceiving chemotherapy without bone marrow transplantation for
acute myelogenous leukemia and those receiving therapy for acute
lymphoblastic leukemia or salvage or dose-intensified chemother-
apy followed by autologous bone marrow transplantation for high-
grade malignant non-Hodgkin's lymphoma were stratified into 2
groups.
The study drug was administered at the patient's discretion ei-
ther orally or by iv infusion. For patients with an estimated creati-
nine clearance < 40 mL/min, the dosing interval of the study drug
was doubled; for those with clearance <20 mL/min, it was tripled.
Prophylaxis was continued during hospitalization until one of
the following end points was reached: stable neutrophil count >0.5
X 109/L, systemic antifungal therapy begun because of suspected
or proven fungal infection, empiric iv amphotericin B therapy
begun, toxicity precluding further administration ofthe study drug,
or death. Some patients were withdrawn from the study because
they were released from the hospital without signs of infection
and with either rapidly increasing neutrophil counts or refractory
leukemia and <0.5 X 109 neutrophils/L.
Three patients in the fluconazole group were replaced because
of neutrophil counts >0.5 X 109 cells/L or for major protocol
violations. The first patient was taken off the study drug for safety
reasons (liver function test results > 3 times normal value) before
his neutrophil count declined to < 1.0 X 109 cells/L. The second
patient inadvertently received commercial fluconazole, and the
third patient was placed on iv amphotericin B at the beginning of
his first febrile episode. These patients were replaced during the
study before the code was broken and, therefore, were not included
in the efficacy analyses, with the exception of a complementary
intention-to-treat analysis.
Patients were evaluated daily by 1 study nurse from the start of
the study until hospital discharge. At baseline and weekly thereaf-
ter, the nurse inspected the oral mucosa, recorded lesions, and
collected specimens for fungal cultures and microscopic examina-
tion. She also recorded daily compliance with administration of
the study drug. Chest radiographs were obtained at baseline, and
levels of creatinine, electrolytes, AST, ALT, and alkaline phospha-
tase were measured weekly during the study. Complete blood cell
counts, including a differential white blood cell count, were ob-
tained daily from the beginning of the study until hospital dis-
charge. Body temperature was recorded twice daily. With each
febrile episode (temperature >38°C), patients were given a physi-
cal examination, blood and urine were cultured, and chest radio-
graphs were obtained.
Antibacterial therapy. Antibacterial prophylaxis was not used;
however, ceftazidime or piperacillin (B-Iactam antibiotics) com-
bined with netilmicin or amikacin (aminoglycoside antibiotics)
were initiated on an empiric basis according to recent guidelines
[11, 12]. Antibiotics were given to all patients who developed
fever >38.4°C (single measurement) or >38°C (on 2 consecutive
measurements) unless a febrile reaction to blood products was the
suspected cause of fever. Empiric antibiotic therapy was adjusted
according to microbiologic culture results and sensitivity tests,
but patients always remained on a broad-spectrum antibacterial
regimen consisting of two antibiotics. If fever of unknown cause
persisted for >48 h, patients were given a second complete work-
up, including a physical examination, chest radiographs, and blood
cultures. Clinical deterioration often resulted in changes to the
empiric antibiotic regimen, at the discretion of the staff.
Antifungal therapy. Besides the study medication, patients re-
ceived no routine antifungal prophylaxis. They were cared for in
open wards without high-efficiency particulate air filters. Mouth
washes with 0.2 % chlorhexidine were done 6 times daily. Use of
topical amphotericin B was permitted if staff suspected mucosal
fungal infection, and it was used 5 times in the fluconazole group
and 10 times in the placebo group. No other antifungal therapy
was allowed. Empiric therapy with parenteral amphotericin B was
initiated according to strict guidelines used for years at our center
[19]: If a febrile episode persisted ;:::96 h without response to
empiric antibiotic therapy and had no documented etiology, pa-
tients underwent a reevaluation, including a clinical examination,
blood cultures for fungi and bacteria, chest radiographs, and if the
latter were not conclusive, a computed tomography (CT) scan of
the lungs. Patients with chest radiographs or CT scans showing
pulmonary infiltrates at the outset of a new febrile episode or with
a CT scan confirming sinusitis were placed on amphotericin B
immediately. The drug was withheld for 72 h in patients for whom
a CT scan of the chest excluded pulmonary consolidations or a
pleural pathology.
The usual dosage of amphotericin B was 1 mg/kg/day accompa-
nied for the first 3 days by 100 mg/kg/day of iv flucytosine given
in three divided doses. At the beginning of iv amphotericin B, the
study drug was stopped to avoid possible antagonism [13, 20].
Evaluation of efficacy ofantifungal prophylaxis. Primary end
points were oropharyngeal candidiasis, deep fungal infection, and
empiric use of iv amphotericin B. Oropharyngeal candidiasis was
diagnosed with or without symptoms by the demonstration ofyeast
by microscopy or culture and by the presence of friable white
oral lesions or erosions covered with exudative material. Systemic
prophylaxis was considered to have failed if iv empiric amphoteri-
cin B was started or the diagnosis of definite or probable fungal
infection was made. The following definitions were used: definite
fungal infection -demonstration of hyphae or yeast in biopsy
specimens or autopsy tissues or of yeast in blood cultures, probable
fungal infection-demonstration of hyphae or yeast by micros-
copy as well as culture in material from lesions in not necessarily
sterile sites, fever of undetermined origin not responding to >96-
h of antibiotic therapy with pulmonary infiltrates showing on chest
radiograph or CT scan, and fever of undetermined origin without
pulmonary infiltrates not responding to >96-h of antibiotic treat-
ment.
Analysis of infection-related health care costs. Cost factors
related to the management of fever and infection complications
were selected before the code was broken and quantified for the
151 evaluable chemotherapy episodes. These factors included the
duration of hospitalization, the number ofmicrobiologic and radio-
logic studies ordered, and the number and duration of systemic
antifungal and antibacterial therapies prescribed. Prices were ob-
tained from the hospital administration or pharmacy at the end of
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Table 1. Characteristics of study population at randomization.
Placebo Fluconazole
(n = 76) (n = 75) P
Acute myelogenous leukemia 54 (71) 55 (73) .85*
High-grade malignant NHL 22 (29) 20 (27) .85*
NHL with autologous bone 7 (9) 8 (11) .79*
marrow transplantation
First course of chemotherapy 24 (32) 26 (34) .86*
Glucocorticoid use during 19 (25) 27 (36) .17*
study
Age, years::':: SD (range) 40 ::':: 13 39 ::':: 13 .45t
(17-71) (17-67)
Neutrophil count (X 109/L) 3.04::':: 3 5.00::':: 8 .23 t
Creatinine level (zzmol/L) 84::':: 16 84::':: 18 .92t
NOTE. NHL = non-Hodgkin's lymphoma. Data are no. (%) of subjects,
mean::':: SD, or as otherwise noted.
* Fisher's exact test.
t Mann-Whitney U test.
August 1993. The costs in Swiss franks were converted to US
dollars by applying an exchange rate of 1.0:1.15.
The results of the health cost analysis prompted a post-hoc
analysis, after breaking the code, of the duration of neutropenia
and frequency of bacteremia in the study population.
Statistical analysis. Before breaking the code, critical deci-
sions (i.e., diagnosis of mycoses or declaring an episode nonevalu-
able) were discussed with an independent external infectious dis-
ease specialist not involved in the study. Results are given for all
episodes except the three nonevaluable ones, which were included
only in the intention-to-treat analysis. Kaplan-Meier analysis, t
tests (normal distributions), and Mann-Whitney U tests (other than
normal distributions) were done using the SATISTICA (StatSoft,
Tulsa, OK) computer program. Frequency tables were computed
by Instat (GraphPad, San Diego), Fisher's exact test (for numbers
<200), and the X2 test (for higher numbers). Results of two-tailed
tests are given.
Results
Baseline characteristics. Among 173 consecutive eligible
patient episodes, 167 were screened (6 courses of chemother-
apy were missed for administrative reasons), and 154 patients
were enrolled into the study (5 patients refused to participate,
4 had received systemic antifungal drugs in the preceding 7
days, and 4 had impaired liver function). Three of the 154
patient episodes were nonevaluable. Randomization of patient
episodes resulted in an equal distribution of baseline character-
istics. No significant differences were found between the 2
groups with regard to sex, weight, height (data not shown), age,
primary diagnosis (acute myelogenous leukemia or lymphoma!
acute lymphatic leukemia with or without autologous bone
marrow transplantation), use of glucocorticoids, kidney func-
tion, or baseline neutrophil count. The number of patients un-
dergoing a first course of chemotherapy (table 1) and the pro-
portion of patients with oral fungal colonization at study entry
(see below) were comparable in both groups.
Effect ofprophylaxis on amphotericin B use. In 61 of 151
episodes, iv amphotericin was given according to preset guide-
lines: 25 of 75 patients in the fluconazole group and 36 of 76
in the placebo group received iv amphotericin B (P = .098).
While the proportion of patients receiving iv amphotericin B
was not significantly different in the 2 groups, a Kaplan-Meier
analysis of the time to failure (i.e., the time until the beginning
of iv amphotericin B) showed that iv amphotericin B was
administered earlier in the placebo group than in the flucona-
zole group (figure I; log rank test, P = .003). Patients receiving
fluconazole prophylaxis remained on the study drug for a mean
of26.6 days (median, 25.0) compared with 20.28 days (median,
20.0) for the placebo group.
The finding that fluconazole prophylaxis delayed the need for
iv amphotericin B was not changed when the 3 nonevaluable
treatments were included in an intention-to-treat analysis (n =
154; log rank test, P = .003). Patients in the placebo group
received amphotericin B for a total of 728 days, compared with
547 days for patients in the fluconazole group. The difference
between the average duration ofiv amphotericin B therapy (7.3
and 9.6 days in the fluconazole and placebo groups, respec-
tively) did not, however, reach statistical significance (P =
.238, Mann-Whitney U test).
Because fluconazole was associated with a delay in starting
amphotericin B and because the decision to start iv amphoteri-
cin B was made mainly on the basis of the extent and duration
of fever (table 2), one would anticipate that patients. in the
fluconazole group had fewer febrile days during the' study.
Indeed, the percentage of febrile (fever :?:38°C) days was sig-
nificantly lower in patients receiving fluconazole than in the
control group (figure 1). From this observation, it can be extrap-
olated that amphotericin B was given as planned.
Also in subgroup analyses, fluconazole prophylaxis delayed
the use ofiv amphotericin B in patients with acute myelogenous
leukemia (n = 109; log rank test, P =.004), in patients who
Table 2. Indications for starting intravenous (iv) amphotericin B
therapy in the 2 study groups.
Placebo Fluconazole Total
Indication (n = 76) (n = 75) (n = 151)
FUO 23 12* 35
FUO plus infiltrate 6 5 11
Probable deep fungal infection 1 2 3
Deep fungal infection 6 6 12
Total 36 25 t 61
NOTE. Data are no. of subjects. Empiric amphotericin B was started in
patients with fever of unknown origin (FUO) refractory to antibiotic therapy
for :;.96 h. In patients with FUO associated with new pulmonary infiltrate or
clinical sinusitis confirmed by computed tomography scan, iv amphotericin B
was started without delay at time of empirical antibiotic therapy.
* Fisher's exact test vs. placebo, P = .05.
t Fisher's exact test, not significant.
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Table 4. Clinical outcome at end of hospitalization for patients
given placebo or fluconazole.
NOTE. Data are no. of subjects. For all comparisons P > .1 by Fisher's
exact test.
* All infections were ultimately cured.
tIn 3 patients, absence of fungal infection was confirmed at autopsy. In 1
control patient, no autopsy was done despite presence of sepsis syndrome of
undetermined cause; clinically, no fungal infection was suspected.
mycosis with extended intestinal and hepatic infarction. The
second patient in the placebo group died with septic shock and
negative blood cultures but with extensive invasive gastrointes-
tinal candidiasis involving the stomach and the entire small
intestine, as documented at autopsy. All remaining patients
were cured of their fungal infections during hospitalization or
after continuous antifungal therapy as outpatients (table 4).
There was no significant difference between the 2 groups with
respect to overall outcome.
Effects ofprophylaxis on oropharyngeal colonization. The
number ofpatients colonized by Candida species at study entry
did not differ between the groups. During weekly microbiologic
surveillance, the number of patients with oral Candida coloni-
zation increased in the placebo group but decreased in patients
receiving fluconazole (table 5). About half of the patients had
oral lesions or oral symptoms during the study, but frequently
no association with candidiasis was found. The number of
patients with an oral pathology was not significantly different
between the 2 prophylaxis groups (table 5). De novo oral colo-
nization with non-albicans species of Candida resistant to flu-
conazole was not observed during the study (table 5).
Clinical side effects and abnormal laboratory values. Ad-
verse events are common in patients undergoing intensive che-
motherapy for hematologic neoplasias. A cause-effect relation-
ship between event and a particular drug is difficult to establish.
Therefore, all registered adverse events for the fluconazole and
placebo groups were compared, and no significant differences
were found. There was no trend toward an increase in the
number of skin reactions or pathologic liver function tests in
patients receiving fluconazole (data not shown).
Effects ofprophylaxis-related health care costs. Besides
the costs for fluconazole and iv amphotericin B, possible effects
of prophylaxis on predetermined health care costs related to
Table 3. Number of fungal infections per treatment group.
Placebo Fluconazole
(n = 76) (n = 75)
Mucocutaneous mycoses, oropharyngeal
candidiasis 9 1*
Deep fungal infections
Disseminated candidiasis 4 o'
Aspergillosis 3 5
Zygomycosis 0 1
Probable aspergillosis 1 2
Total proven or probable deep
mycoses 8 8
Pulmonary infiltrates with antibiotic-
refractory fever 6 5
Total definite, probable, and possible
deep mycoses 14 13
NOTE. Deep fungal infections included disseminated candidiasis due to
Candida parapsillosis (1 case), septic shock with invasive candidiasis of stom-
ach and the entire small intestine (l), chronic disseminated candidiasis (2),
disseminated zygomycosis causing infarcts ofliver and intestine (l), Aspergil-
lus pneumonia with or without dissemination (8 definite and 3 probable).
p = * .018 or t .12, Fisher's exact test.
underwent a first course of chemotherapy (n = 50; log rank
test, P = .005), and in patients enrolled for the first time into
the study (n = 96; P = .009).
Effect ofprophylaxis on fungal infections. Patients receiv-
ing fluconazole prophylaxis developed significantly fewer mu-
cosal infections with Candida species (P = .018; table 3).
Oral thrush, oral lesions, and yeast developed in 1 fluconazole
patient and 9 placebo patients. In 2 patients, oropharyngeal
candidiasis was present at randomization, and both were ran-
domized to the fluconazole group. One of these patients healed
within 1 week using the study drug alone; the other also re-
ceived topical amphotericin B and healed within 2 weeks. The
study design permitted topical use of amphotericin B for oral
lesions. This had a limited effect on the interpretation of the
prophylactic efficacy of fluconazole on oropharyngeal candidi-
asis. Among the 5 patients receiving amphotericin B in the
fluconazole group, 1 (mentioned above) had thrush at study
entry and a second developed it during the study. In the 3
others, candidiasis was excluded as the cause of oral lesions by
fungal cultures and direct microscopy. In contrast, 10 patients
received topical amphotericin B in the control group, among
whom 7 had microbiologically documented thrush.
The number of deep mycoses was not affected by fluconazole
prophylaxis. There were no cases of invasive candidiasis during
fluconazole prophylaxis, but there were 4 cases in the control
group; however, there were 4 probable or definite fungal infec-
tions caused by molds in the placebo group and 8 cases oc-
curred in the fluconazole group (two-tailed Fisher's exact test,
P = .36; table 3). Two patients in each group died with a
fungal infection. One patient in each group died with extensive
pneumonia caused by Aspergillus fum igatus. An additional pa-
tient from the fluconazole group died of abdominal zygo-
Outcome
Hematologic response to
chemotherapy, no deep fungal
infection
Refractory leukemia, no fungal
infection
Hematologic response, on systemic
antifungal therapy for suspected or
proven deep fungal infection*
Died with deep fungal infection
Died without deep fungal infectiont
Placebo
(n = 76)
62
2
7
2
3
Fluconazole
(n = 75)
60
2
10
2
2
lID 1995; 172 (October) Fluconazole Prophylaxis during Chemotherapy 1039
Table 5. Effects of fluconazole prophylaxis on oral colonization
with Candida species and oral pathology.
NOTE. Data are no. of subjects. Samples for microbiologic studies were
obtained by oral swab at study entry, weekly during study, and when therapy
for oropharyngeal candidiasis was started.
* Fisher's exact test.
t Most isolates were Candida albicans. Other Candida species were 1 each
of C. lusitaniae, C. norvegensis, and C. tropicalis at study entry, 2 of C.
glabrata during fluconazole prophylaxis, and 2 of C. krusei and 1 of C.glabrata
during placebo treatment.
t Epithelial defects (erosions or ulceration) or frank thrush (white fur) with
or without symptoms.
the management of fever and infection were evaluated with
the expectation that a reduction in the number of febrile days
or a reduced need for iv amphotericin B would reduce costs.
No significant difference was found in the most important cost
factor, duration of hospitalization, even though fluconazole pa-
tients were hospitalized an average of 1.6 days longer. Patients
in the fluconazole group received iv amphotericin B on 23.9%
fewer days but received parenteral antibiotics on 22.1% more
days (table 6). This was unexpected in view of the reduced
proportion of febrile days in patients treated with fluconazole
(figure 1).
Before treatment
Direct microscopy positive for
Candida species
Culture positive for Candida
species'
Oral pathologic findings'
During treatment
Direct microscopy positive for
Candida species
Culture positive for Candida
species"
Oral pathologic findings!
Placebo
(n = 76)
6
14
5
14
28
39
Fluconazole
(n = 75)
10
17
8
6
32
p*
.30
.55
.40
<.001
<.001
.33
In accordance with the fewer febrile days in the fluconazole
group, the number of examinations prompted by fever was also
lower in that group (table 6). While none of the differences
between the mean values of these parameters reached statistical
significance, the fraction of hospital days on which iv ampho-
tericin B or parenteral antibiotics were given was significantly
different among the 2 groups (P < .001 for all four compari-
sons; table 6). In summary, we found that fluconazole did not
reduce the limited number of evaluated infection-related health
care costs, which tended to be higher (12.3%, P = .060) in
the fluconazole group (table 6).
Secondary analysis of the duration of neutropenia and the
occurrence ofbacteremia. The association of fluconazole ad-
ministration with significantly more days of antibiotic therapy,
despite fewer febrile days, suggested that fluconazole prophy-
laxis was associated with prolonged neutropenia. Antibiotics
were not discontinued even if the patient was well and afebrile,
if neutrophil counts were <0.1 X 109/L [11, 12]. We therefore
did a post-hoc secondary analysis. In the fluconazole group,
the mean duration of neutropenia «0.5 X 109 cells/L) was
23.78 days (95% confidence interval [CI], 20.75-26.81) com-
pared with 19.5 days in the control group (95% CI, 17.29-
21.70; Mann-Whitney U test, P = .067). The difference be-
tween the duration of severe neutropenia «0.1 X 109 cells/
L) was clear-cut, with no overlap of the 95% CIs between the 2
groups; it was 16.2 days (95% CI, 13.91-18.48) in fluconazole
patients and 12.13 days (95% CI, 10.61-13.65; n = 151; P =
.01) in the placebo group.
The fluconazole group had a total of 2883 hospital days for
75 patient episodes. On 1784 of these days, neutrophil counts
were <0.5 X 109/L, and on 1215 days they were <0.1 X 109/
L. In comparison, there were a total of 2796 hospital days for
76 patient treatment episodes observed in the placebo group;
on 1482 of these days, neutrophil counts were <0.5 X 109/L,
and on 922 days they were <0.1 X 109/L (X2 test, P < .001
for both comparisons). This finding may explain the higher
Table 6. Comparison of infection-related health care cost factors for study patients given placebo and
patients given fluconazole.
Placebo Fluconazole
Factor (n = 76) Cost (±95% CI) (n = 75) Cost (±95% CI)
Hospital days 36.8 25,912 (22,863-28,961) 38.4* 27,075* (24,202-29,947)
Days on fluconazole 0 0 26.6 2157 (1940-2375)
Days on intravenous
amphotericin B 9.6 401 (217-586) 7.3* 305* (154-457)
Days on parenteral antibiotics 17.2 3726 (3157-4294) 21.0 4551 t (3862-5241)
Blood cultures 7.9 414 (342-487) 7.3* 379* (310-448)
Chest radiographs 4.61 476 (396-557) 4.01 * 415* (345-485)
Computed tomography scans 0.72 629 (304-955) 0.64* 492* (304-680)
Total for evaluated factors 31,559 (27,754-35,364) 35,440 t (31,687-39,193)
NOTE. Data are mean costs in US dollars or mean no. of subjects, as appropriate, per treatment. Fees were those
on 31 August 1993. CI = confidence interval.
* Mann-Whitney U test, * P > .1, t P = .084; t P = .060.
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among the 76 patients receiving placebo (P = .07). This differ-
ence was mainly due to an excess in the number of gram-
negative bacteremia (11 vs. 4; P = .061) that were mainly
caused by enteric gram-negative rods.
Discussion
In this single-center study, in which aspergillosis was the
predominant mycosis in patients undergoing intensive chemo-
therapy for remission induction of hematologic neop1asias, the
number of cases of systemic mycoses was not reduced by
fluconazole prophylaxis. While no case of invasive candidiasis
occurred in the fluconazole group, this advantage was offset
by an increased number of definite or probable infections with
molds. In agreement with results from comparable studies [2,
14, 15], fluconazole prophylaxis in our study did not affect
overall mortality or mortality from fungal infections and did
not influence the immediate success ofanticancer therapy. Also
in agreement with results in other studies [2, 14, 15,21], fluco-
nazole prophylaxis reduced oral colonization with Candida
species and the occurrence of oral thrush .
In contrast to the present study and others with a < 10%
frequency of disseminated candidiasis [2, 15], a randomized,
double-blind, multicenter study done in allogeneic bone mar-
row recipients found a significant reduction of deep mycoses
during fluconazole prophylaxis and a reduced number ofdeaths
with fungal infections [8]. The study had a high percentage
(16%) of systemic Candida albicans infections among placebo
recipients, but mortality and overall prognosis were again not
affected by fluconazole prophylaxis.
In our study, fluconazole reduced by 20% the number of
febrile days and, thereby, delayed the need for iv amphotericin
B. However, neither the proportion of patients requiring am-
photericin B nor the mean duration of amphotericin B therapy
was significantly reduced by fluconazole prophylaxis. This ob-
servation raises the question whether an important proportion
of febrile episodes not responding to antibacterial agents during
severe neutropenia is due to fungi. It is conceivable that the
mucosal fungal flora of the gastrointestinal tract, after translo-
cation facilitated by mucosa] damage and neutropenia, is re-
sponsible for a systemic febrile inflammatory reaction in many
of these patients, even without causing a clinically apparent
mycosis. It is noteworthy in this regard that another placebo-
controlled study recently suggested a reduction of fever by
fluconazole prophylaxis in bone marrow transplant patients
[22].
Since most studies have demonstrated that the efficacy of
prophylactic antifungal agents is limited to infections with sus-
ceptible strains of Candida species and that such agents do not
affect the frequency of systemic mycoses, mortality, or overall
outcome, we questioned whether fluconazole prophylaxis
would affect health care costs. Since fluconazole reduced the
number offebrile days in our study, it would also be expected to
reduce the number ofantibiotic prescriptions and investigations
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proportion of days on parenteral antibiotics among the fluco-
nazole group (1578/2883 hospital days) than among the placebo
group (1307/2796 days) (P < .001).
Because randomization was not stratified according to che-
motherapy but only according to the type of hematologic neo-
plasia, it was important to assure that the association between
prolonged neutropenia and fluconazole prophylaxis was not
due to an inadvertent mismatch (e.g., in the type or intensity of
chemotherapy). Therefore, extensive subgroup analyses were
added. These analyses did not indicate that a mismatch with
respect to intensity or cycle number of chemotherapy was re-
sponsible for the association between prolonged neutropenia
and fluconazole. Patients with a blood neutrophil count >0.1
X 109 neutrophils/L after a single course of chemotherapy (n
= 147; P = .005), patients randomized for the first time into
the study (n = 96; P = .032), or patients receiving a first
course of chemotherapy (n = 50; P = .004) had a significant
association of prolonged severe neutropenia «0.1 X 109/L)
and fluconazole prophylaxis. Also of note, the largest patient
group receiving the same type of chemotherapy (a single course
of daunorubicin combined with cytosine arabinoside) for acute
leukemia had a strong and statistically significant association
between prolonged neutropenia and fluconazole prophylaxis (n
= 54; P =.025).
Because severe neutropenia increases the susceptibility to
bacterial infections, we also studied retrospectively whether
fluconazole increased the number of bacteremic episodes in
the study population. Among the 75 patients receiving fluco-
nazole, 27 had bacteremia, and bacteremia occurred 16 times
Figure 1. Kaplan-Meier plot showing % of patients not receiving
intravenous (iv) amphotericin B at various times. Log rank test, P =
.003. Shown in parallel are no. of patients remaining in study and
cumulative % of study days on which patients were febrile (tempera-
ture ~38°C).
10 20 30 40
DAY OF STUDY
NUMBER OF PATIENTS REMAINING IN STUDY:
- fluconazole 72 54 24 6
- placebo 67 40 12 4
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aimed at the detection of the infectious causes of fever. How-
ever, fluconazole prophylaxis was unexpectedly associated with
a trend toward increased use of parenteral antibiotics and did
not decrease the number of investigations. It is a widely ac-
cepted policy to prescribe antibiotics for episodes of febrile
neutropenia, despite defervescence, until granulocyte counts
exceed 0.1 X 109 cells/L [11, 12]. Prolonged neutropenia was
therefore suspected as the reason that more antibiotics were
prescribed despite the fewer febrile episodes in the fluconazole
group.
Post-hoc analysis showed that the fluconazole patients had
a 32% increase in the number of days with severe neutropenia
«0.1 X 109/L). This secondary analysis also suggested a trend
toward an excess of gram-negative bacteremia in the flucona-
zole group. It is not conceivable and none of the subgroup
analyses indicated that the difference in the duration of severe
neutropenia in the fluconazole and the placebo groups was
due to a randomization mismatch. Nevertheless, future studies
should prospectively address this question, especially because
the mechanism responsible for the observed associations re-
mains unclear. Others have made similar observations in a
controlled study of ketoconazole prophylaxis in hematologic
patients and speculated on the possibility of a drug interaction
with antineoplastic drugs, resulting in an increased cytotoxic
activity [4]. Another recent study demonstrated that fungal
prophylaxis was associated with an increased risk for bacter-
emia without explaining its cause [23].
The routine prophylactic use of fluconazole in severely neu-
tropenic patients reduces the number of infections with Can-
dida species, particularly oropharyngeal candidiasis, and delays
the need for iv amphotericin B. However, this primary interven-
tion does not affect the overall outcome for patients, presum-
ably because fluconazole does not reduce the frequency of mold
infections. Therefore, the routine use of fluconazole prophy-
laxis during intensive chemotherapy of hematologic neoplasias
is not supported by the findings in this study. However, local
epidemiologic data should be considered. Fluconazole prophy-
laxis should be considered in centers in which the frequency
of deep infections caused by azole-susceptible yeasts is > 10%.
When mold infections are a problem, other strategies should
be investigated, such as the use of compounds that are active
against both molds and Candida species. Future clinical studies
should prospectively investigate the effects of antifungal pro-
phylaxis on the duration of neutropenia and the frequency of
bacteremia.
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